G
Gajanan Sapkal
Researcher at Indian Council of Medical Research
Publications - 21
Citations - 660
Gajanan Sapkal is an academic researcher from Indian Council of Medical Research. The author has contributed to research in topics: Immunogenicity & Vaccination. The author has an hindex of 9, co-authored 21 publications receiving 219 citations.
Papers
More filters
Journal ArticleDOI
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.
Raches Ella,Siddarth Reddy,William C. Blackwelder,Varsha Potdar,Pragya D Yadav,Vamshi Sarangi,Vinay Kumar Aileni,Suman Kanungo,Sanjay K Rai,P. Prabhakar Reddy,Savita Verma,Chandramani Singh,Sagar Vivek Redkar,Satyajit Mohapatra,Anil Pandey,Pajanivel Ranganadin,Raghavendra Gumashta,Manish Multani,Shameem Mohammad,Parul Bhatt,Laxmi Kumari,Gajanan Sapkal,Nivedita Gupta,Priya Abraham,Samiran Panda,Sai Prasad,Balram Bhargava,Krishna Murthy Ella,Krishna Mohan Vadrevu +28 more
TL;DR: In this article, the authors reported the clinical efficacy against COVID-19 infection of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) in Indian adults.
Posted ContentDOI
Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase 3 trial
Raches Ella Mbbs,Siddharth Reddy,William C. Blackwelder,Varsha Potdar,Pragya D Yadav,Vamshi Sarangi,Vinay Kumar Aileni,Suman Kanungo,Sanjay K Rai,P. Prabhakar Reddy,Savitha Verma,Chandramani Singh,Sagar Vivek Redkar,Satyajit Mohapatra,Anil Kumar Pandey,Pajanivel Ranganadin,Raghavendra Gumashta,Manish Multani,Shameem Mohammad,Parul Bhatt,Laxmi Kumari,Gajanan Sapkal,Nivedita Gupta,Priya Abraham,Samiran Panda,Sai Prasad,Balram Bhargava,Krishna Murthy Ella,Krishna Mohan Vadrevu +28 more
TL;DR: A double-blind, randomised, multicentre, phase 3 clinical trial in 25 Indian hospitals to evaluate the efficacy, safety, and immunological lot consistency of BBV152, a whole-virion inactivated SARS-CoV-2 vaccine formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum as discussed by the authors.
Journal ArticleDOI
Th1 Skewed immune response of Whole Virion Inactivated SARS CoV 2 Vaccine and its safety evaluation.
Brunda Ganneru,Harsh Jogdand,Vijaya Kumar Daram,Dipankar Das,Narasimha Reddy Molugu,Sai Prasad,Srinivas V. Kannappa,Krishna Murthy Ella,Rajaram Ravikrishnan,Amit Awasthi,Jomy Jose,Panduranga Rao,Deepak Kumar,Raches Ella,Priya Abraham,Pragya D Yadav,Gajanan Sapkal,Anita Shete-Aich,Gururaj Rao Desphande,Sreelekshmy Mohandas,Atanu Basu,Nivedita Gupta,Krishna Mohan Vadrevu +22 more
TL;DR: In this article, the safety and immunogenicity of a whole virion inactivated (WVI) SARS-CoV-2 vaccine (BBV152), adjuvanted with aluminum hydroxide gel (Algel), or TLR7/8 agonist chemisorbed Algel, were evaluated in mice, rats, and rabbits.
Journal ArticleDOI
Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model
Sreelekshmy Mohandas,Pragya D Yadav,Anita Shete-Aich,Priya Abraham,Krishna Mohan Vadrevu,Gajanan Sapkal,Chandrashekhar Mote,Dimpal A Nyayanit,Nivedita Gupta,V.K. Srinivas,Manoj Kadam,Abhimanyu Kumar,Triparna Majumdar,Rajlaxmi Jain,Gururaj Deshpande,Savita Patil,Prasad Sarkale,Deepak Y. Patil,Raches Ella,Sai Prasad,Sharda Sharma,Krishna Murthy Ella,Samiran Panda,Balram Bhargava +23 more
TL;DR: In this paper, the authors assessed the immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidates BBV152A,BBV152B, and BBV 152C in Syrian hamsters.
Posted ContentDOI
SARS CoV-2 variant B.1.617.1 is highly pathogenic in hamsters than B.1 variant
Pragya D Yadav,Sreelekshmy Mohandas,Anita M. Shete,Dimpal A Nyayanit,Nivedita Gupta,Deepak Y. Patil,Gajanan Sapkal,Varsha Potdar,Manoj Kadam,Abhimanyu Kumar,Sanjay Kumar,Deepak Suryavanshi,Chandrashekhar Mote,Priya Abraham,Samiran Panda,Balram Bhargava +15 more
TL;DR: This study demonstrates higher pathogenicity in hamsters evident with reduced body weight, higher viral load in lungs and pronounced lung lesions as compared to B.1.617.1, the new SARS-CoV-2 lineage that emerged in India.